Insider Selling: Baxter International Inc (BAX) SVP Sells $2,000,883.29 in Stock
Baxter International Inc (NYSE:BAX) SVP Scott Pleau sold 27,197 shares of Baxter International stock in a transaction dated Monday, June 25th. The stock was sold at an average price of $73.57, for a total value of $2,000,883.29. Following the transaction, the senior vice president now owns 47,363 shares in the company, valued at $3,484,495.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
BAX opened at $73.84 on Friday. Baxter International Inc has a 1 year low of $58.81 and a 1 year high of $75.62. The stock has a market capitalization of $39.52 billion, a price-to-earnings ratio of 28.28, a PEG ratio of 1.91 and a beta of 0.81. The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.03 and a current ratio of 2.63.
Baxter International (NYSE:BAX) last released its quarterly earnings results on Thursday, April 26th. The medical instruments supplier reported $0.70 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.08. Baxter International had a return on equity of 15.70% and a net margin of 7.75%. The firm had revenue of $2.68 billion for the quarter, compared to the consensus estimate of $2.62 billion. During the same quarter last year, the business posted $0.58 EPS. The company’s revenue for the quarter was up 8.2% on a year-over-year basis. analysts expect that Baxter International Inc will post 2.89 EPS for the current fiscal year.
Several research analysts have weighed in on the company. Zacks Investment Research lowered Baxter International from a “buy” rating to a “hold” rating in a report on Thursday, May 31st. ValuEngine lowered Baxter International from a “buy” rating to a “hold” rating in a report on Wednesday, March 7th. Bank of America lifted their target price on Baxter International from $73.00 to $83.00 and gave the stock a “buy” rating in a report on Tuesday, May 22nd. Finally, Piper Jaffray Companies assumed coverage on Baxter International in a report on Thursday, May 17th. They set an “overweight” rating and a $77.00 target price on the stock. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Baxter International presently has an average rating of “Buy” and a consensus target price of $73.25.
Several large investors have recently added to or reduced their stakes in BAX. Robecosam AG acquired a new stake in shares of Baxter International in the fourth quarter valued at about $103,000. Ostrum Asset Management acquired a new stake in shares of Baxter International in the first quarter valued at about $121,000. IHT Wealth Management LLC increased its position in shares of Baxter International by 71.9% in the first quarter. IHT Wealth Management LLC now owns 2,462 shares of the medical instruments supplier’s stock valued at $156,000 after acquiring an additional 1,030 shares during the last quarter. Truewealth LLC acquired a new stake in shares of Baxter International in the fourth quarter valued at about $159,000. Finally, Summit Trail Advisors LLC increased its position in shares of Baxter International by 6,961.5% in the first quarter. Summit Trail Advisors LLC now owns 161,427 shares of the medical instruments supplier’s stock valued at $161,000 after acquiring an additional 159,141 shares during the last quarter. 83.44% of the stock is currently owned by institutional investors and hedge funds.
About Baxter International
Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.